Abstract
The anticancer activity of mistletoe (Viscum album L.) lectins and proteins extracts has been demonstrated in numerous in vitro and in vivo studies, including the validation of their clinical efficacy. Mistletoe tissue culture has been suggested as an approach for standardizing lectin biosynthesis, while the biosynthesis of novel lectins through somaclonal variation, i.e. the epigenetic modulation of the genome in vitro has also been demonstrated. However, the tumor cytotoxic properties of these novel molecules have not been assessed. PC12 pheochromocytoma and RAW 264.7 macrophage cell cultures were treated with protein extracts from “normal” and somaclonally variant mistletoe callus cultures, as well as donor plants used as positive control. Mistletoe callus-derived extracts demonstrated a concentration-dependent cytotoxicity in cancer cell lines, which was significantly higher compared to donor plants. Extracts from somaclonal cultures were even more potent against tumor cells. Our results suggest that somaclonally variant mistletoe callus cultures could be used as potential cell factories for the production of novel anticancer proteins.
Keywords: Biotechnology, callus culture, cancer, in vitro cytotoxicity, mistletoe (Viscum album L.), somaclonal variation.
Graphical Abstract
Current Bioactive Compounds
Title:Protein Extracts from Somaclonal Mistletoe (Viscum Album L.) Callus with Increased Tumor Cytotoxic Activity in Vitro
Volume: 11 Issue: 2
Author(s): Maria Barberaki, Eirini Dermitzaki, Andrew N. Margioris, Maria Theodosaki, Stylianos Grafakos and Spyridon Kintzios
Affiliation:
Keywords: Biotechnology, callus culture, cancer, in vitro cytotoxicity, mistletoe (Viscum album L.), somaclonal variation.
Abstract: The anticancer activity of mistletoe (Viscum album L.) lectins and proteins extracts has been demonstrated in numerous in vitro and in vivo studies, including the validation of their clinical efficacy. Mistletoe tissue culture has been suggested as an approach for standardizing lectin biosynthesis, while the biosynthesis of novel lectins through somaclonal variation, i.e. the epigenetic modulation of the genome in vitro has also been demonstrated. However, the tumor cytotoxic properties of these novel molecules have not been assessed. PC12 pheochromocytoma and RAW 264.7 macrophage cell cultures were treated with protein extracts from “normal” and somaclonally variant mistletoe callus cultures, as well as donor plants used as positive control. Mistletoe callus-derived extracts demonstrated a concentration-dependent cytotoxicity in cancer cell lines, which was significantly higher compared to donor plants. Extracts from somaclonal cultures were even more potent against tumor cells. Our results suggest that somaclonally variant mistletoe callus cultures could be used as potential cell factories for the production of novel anticancer proteins.
Export Options
About this article
Cite this article as:
Barberaki Maria, Dermitzaki Eirini, N. Margioris Andrew, Theodosaki Maria, Grafakos Stylianos and Kintzios Spyridon, Protein Extracts from Somaclonal Mistletoe (Viscum Album L.) Callus with Increased Tumor Cytotoxic Activity in Vitro, Current Bioactive Compounds 2015; 11 (2) . https://dx.doi.org/10.2174/1573407211666150602215615
DOI https://dx.doi.org/10.2174/1573407211666150602215615 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Safety of Multi-Targeted Kinase Inhibitors as Monotherapy Treatment of Cancer: A Systematic Review of the Literature
Current Drug Safety Hypericin and its Derivatives Act as Radiosensitizing Agents That Can Inhibit Tumor Initiating Cell Viability
Clinical Cancer Drugs Palliative Care in High and Low Resource Countries
Current Pediatric Reviews The Crosstalk Between the Matrix Metalloprotease System and the Chemokine Network in Acute Myeloid Leukemia
Current Medicinal Chemistry Targeting EZH2 for Cancer Therapy: Progress and Perspective
Current Protein & Peptide Science Editorial (Hot Topic: Therapeutic Potential of Fetal Mesenchymal Stem Cells)
Current Stem Cell Research & Therapy Discovery of Selective Probes and Antagonists for G Protein-Coupled Receptors FPR/FPRL1 and GPR30
Current Topics in Medicinal Chemistry DNA Demethylation by TET Proteins: A Potential Therapeutic Target in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Molecular Imaging Aided Improvement in Drug Discovery and Development
Current Biotechnology The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
Current Medicinal Chemistry Role of GSK-3 in Cardiac Health: Focusing on Cardiac Remodeling and Heart Failure
Current Drug Targets The Potential Role of Peritumoral Apparent Diffusion Coefficient Evaluation in Differentiating Glioblastoma and Solitary Metastatic Lesions of the Brain
Current Medical Imaging Actions of the Anti-Angiogenic Compound Angiostatin in an Animal Model of Alzheimer’s Disease
Current Alzheimer Research Novel Possible Pharmaceutical Research Tools: Stem Cells, Gene Delivery and their Combination
Current Pharmaceutical Design Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside
Current Molecular Medicine Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Stimuli-responsive Drug Delivery Nanosystems: From Bench to Clinic
Current Nanomedicine Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) Nanoparticle-Based Tumor Theranostics with Molecular Imaging
Current Pharmaceutical Biotechnology VEGF-VEGFR System as a Target for Suppressing Inflammation and other Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets